

Learning Objectives

After completing this activity, the participant should be better able to:

- Describe the role of risk stratification and upfront therapies in multiple myeloma
- Appraise novel approaches in the treatment of relapsed and refractory multiple myeloma
- Describe emerging novel therapeutic pathways for multiple myeloma
- Describe novel therapies for Hodgkin lymphoma
- Explain the treatment options for aggressive lymphomas
- Cite the novel treatment options for T-cell lymphomas
- Evaluate the risk stratified therapy of chronic lymphocytic leukemia
- Identify updates in the treatment of chronic myelogenous leukemia
- Select appropriate treatment options for myelodysplastic syndromes
- Cite the importance of symptom management and supportive care issues
- Discuss cost and reimbursement issues in the treatment of hematological malignancies